Cargando…

Androgen Deprivation Therapy–Induced Cardiovascular Disease

Detalles Bibliográficos
Autor principal:	Dhanushkodi, Manikandan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2016
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493255/ https://www.ncbi.nlm.nih.gov/pubmed/28717732 http://dx.doi.org/10.1200/JGO.2016.006015

Ejemplares similares

Nasopharyngeal Cancer Outcomes From Saudi Arabia
por: Dhanushkodi, Manikandan
Publicado: (2016)

CARDIOVASCULAR DISEASES AND ANDROGEN DEPRIVATION THERAPY
por: Boban, Marko
Publicado: (2019)

Androgen Deprivation Therapy and Cardiovascular Risk
por: Mourmouris, Panagiotis, et al.
Publicado: (2012)

Cardiovascular Toxicities of Androgen Deprivation Therapy
por: Challa, Azariyas A., et al.
Publicado: (2021)

Cardiovascular Toxicity of Androgen Deprivation Therapy
por: Boland, Julia, et al.
Publicado: (2021)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
por: Corona, Giovanni, et al.
Publicado: (2021)

The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer
por: Shaw, Greg L., et al.
Publicado: (2016)

Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer
por: Roayaei, Mahnaz, et al.
Publicado: (2013)

Androgen-Deprivation Therapy and Cardiovascular Disease Risk – The Role of Exercise in Prostate Cancer Treatment
por: Wall, Bradley
Publicado: (2016)

Androgen Deprivation Therapy and Cardiovascular Risk in Chinese Patients with Nonmetastatic Carcinoma of Prostate
por: Huang, Gang, et al.
Publicado: (2014)

Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer
por: Gheorghe, Gabriela Silvia, et al.
Publicado: (2021)

Cardiovascular Impact of Androgen Deprivation Therapy: from Basic Biology to Clinical Practice
por: Kim, Janice, et al.
Publicado: (2023)

Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy
por: Stensland, Kristian D, et al.
Publicado: (2022)

Metabolic effects of androgen deprivation therapy
por: Choi, See Min, et al.
Publicado: (2015)

AB187. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality
por: Niu, Yuanjie, et al.
Publicado: (2016)

AB125. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality
por: Niu, Yuanjie, et al.
Publicado: (2015)

Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer Patients: A Systematic Review
por: Kakarla, Meghana, et al.
Publicado: (2022)

Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer
por: Fradin, James, et al.
Publicado: (2023)

Influence of age on androgen deprivation therapy-associated Alzheimer’s disease
por: Nead, Kevin T., et al.
Publicado: (2016)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Androgen deprivation therapy increases brain ageing
por: Plata-Bello, Julio, et al.
Publicado: (2019)

Androgen deprivation therapy and the risk of subsequent keratitis
por: Liu, Dai-Wei, et al.
Publicado: (2020)

Duration of Androgen Deprivation Therapy and Cardiovascular Fitness: Delivering the Right Patient the Right Therapy at the Right Time
por: Narayan, Vivek, et al.
Publicado: (2020)

Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation
por: Lipianskaya, Julia, et al.
Publicado: (2014)

Cardiovascular Disease Risk Factors: How Relevant in African Men With Prostate Cancer Receiving Androgen-Deprivation Therapy?
por: Essien, Okon Ekwere, et al.
Publicado: (2016)

Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study
por: Haque, Reina, et al.
Publicado: (2017)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Influence of Baseline Cardiovascular Comorbidities on Mortality after Androgen Deprivation Therapy for Metastatic Prostate Cancer
por: Wu, Szu-Yuan, et al.
Publicado: (2020)

Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
por: Bassey, Iya Eze, et al.
Publicado: (2020)

Androgen deprivation therapy as backbone therapy in the management of prostate cancer
por: Merseburger, Axel S, et al.
Publicado: (2016)

Schizophrenia and neighbourhood deprivation
por: Gage, S H, et al.
Publicado: (2016)

Reply: Prostate cancer, insulin and androgen deprivation therapy
por: Lehrer, S
Publicado: (2003)

Androgen deprivation therapy prevents bladder cancer recurrence
por: Izumi, Koji, et al.
Publicado: (2014)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

Differences in Hypercholesterolemia and Atherogenesis Induced by Common Androgen Deprivation Therapies in Male Mice
por: Poulsen, Christian Bo, et al.
Publicado: (2016)

Supposed pituitary-production of human chorionic Gonadotropin induced by androgen deprivation therapy
por: Yoshimura, Koji, et al.
Publicado: (2019)

Androgen therapy and atherosclerotic cardiovascular disease
por: McGrath, K-CY, et al.
Publicado: (2008)

Metabolic Complications and Increased Cardiovascular Risks as a Result of Androgen Deprivation Therapy in Men with Prostate Cancer
por: Shastri, Bhavin R., et al.
Publicado: (2011)

Reduced Cardiorespiratory Fitness and Increased Cardiovascular Mortality After Prolonged Androgen Deprivation Therapy for Prostate Cancer
por: Gong, Jingyi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rlj39ipbkapck7lmefh8ckpchc